Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP)
Issued Date
2025-01-01
Resource Type
ISSN
00119059
eISSN
13654632
Scopus ID
2-s2.0-105023281242
Journal Title
International Journal of Dermatology
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Dermatology (2025)
Suggested Citation
Goh E., Nielsen M.L., Maul L.V., Didaskalu J.A., Chularojanamontri L., Guevara B.E.K., Ji M., Zheng M., Maul J.T., Oon H.H. Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP). International Journal of Dermatology (2025). doi:10.1111/ijd.70183 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113406
Title
Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP)
Author's Affiliation
Zhejiang University School of Medicine
NUS Yong Loo Lin School of Medicine
Siriraj Hospital
Bispebjerg Hospital
Lee Kong Chian School of Medicine
Universitätsspital Zürich, Dermatologische Klinik
Universität Zürich, Medizinische Fakultät
A-Star, Skin Research Institute of Singapore
Southern Philippines Medical Center
Institute of Skin Disease Prevention and Treatment
NUS Yong Loo Lin School of Medicine
Siriraj Hospital
Bispebjerg Hospital
Lee Kong Chian School of Medicine
Universitätsspital Zürich, Dermatologische Klinik
Universität Zürich, Medizinische Fakultät
A-Star, Skin Research Institute of Singapore
Southern Philippines Medical Center
Institute of Skin Disease Prevention and Treatment
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Psoriasis is a chronic inflammatory skin and systemic disease with a wide range of clinical manifestations and treatment options, including topicals, phototherapy, non-biologic systemic treatments, and biologics. Understanding regional differences in clinical characteristics and treatment patterns can help improve equity and access to care globally. Methods: The Global Healthcare Study on Psoriasis (GHSP) is an ongoing multinational, multicenter, longitudinal observational study. This study included cross-sectional data from 1415 patients across Singapore, China, Thailand, the Philippines, and Switzerland, collected between January 2020 and March 2024 using a 48-item questionnaire assessing clinical characteristics, comorbidities, disease severity, quality of life, and treatment patterns. Results: Plaque psoriasis was the predominant phenotype (90.5%). Mean Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores were highest in China and the Philippines. Topical therapy was the most adopted treatment modality in both Asia (79.8%) and Switzerland (96.7%). Phototherapy usage was highest in Switzerland (59.0%) and Singapore (65.4%). Non-biologic systemic agents were more frequently prescribed in Switzerland (64.0%), Singapore (63.2%), and Thailand (84.7%) than in China (20.0%) and the Philippines (29.1%). Methotrexate was the predominant non-biologic except in China, where retinoids predominated. Biologic uptake was highest in Switzerland (59.5%) and Singapore (31.6%) and limited elsewhere by affordability, availability, and preference. Interleukin-17A inhibitors were the most prescribed class. Biosimilar use was low (3.0%). Conclusions: Our analysis revealed marked disparities in access to biologic treatment and reiterates the need to improve availability and affordability, through greater adoption of biosimilars and enhanced financial support.